Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to provide an update on the Company’s market authorisation study for nerve repair device, Remplir™.
This week, the Company announced the successful completion of the first stage of this study, with all nerve repair surgeries performed without adverse events.
This milestone marks an important step in Orthocell’s global expansion and pursuit of US market clearance, expected in the early months of 2025.